Skye Bioscience, Inc. (SKYE) Operating cash flow 2016–2025
Skye Bioscience, Inc. (SKYE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$43.1MFY2025 · since FY2016: -$3.6M → -$43.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$43.1M | -70.6% |
| FY2024 | -$25.2M | -80.9% |
| FY2023 | -$14.0M | -9.5% |
| FY2022 | -$12.7M | -96.8% |
| FY2021 | -$6.5M | -6.9% |
| FY2020 | -$6.1M | -0.4% |
| FY2019 | -$6.0M | -52.9% |
| FY2018 | -$3.9M | -18.4% |
| FY2017 | -$3.3M | +6.2% |
| FY2016 | -$3.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SKYE financial trends
SKYE RevenueSKYE Net incomeSKYE Net marginSKYE Gross profitSKYE Gross marginSKYE Operating incomeSKYE Operating marginSKYE Free cash flowSKYE Capital expendituresSKYE Return on equitySKYE Stock buybacksSKYE Dividends paidSKYE Total assetsSKYE Total liabilitiesSKYE Shareholders’ equitySKYE overview →